PD-166793

PD-166793 is a potent, selective, orally active and wide-broad spectrum inhibitor of MMP, exhibiting nanomolar potency against MMP-2, MMP-3 and MMP-13 (IC50=4, 7, and 8 nM, respectively) and micromolar potency vs MMP-1, -7 and -9 (IC50=6.0, 7.2, and 7.9 μM, respectively) . PD-166793 can attenuate left ventricular remodeling and dysfunction in a rat model of progressive heart failure[1][2][3].

Product Specifications

CAS Number

[199850-67-4]

UNSPSC

12352005

Target

MMP

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/pd-166793.html

Purity

99.21

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C)[C@@H](C(O)=O)NS(=O)(C1=CC=C(C2=CC=C(Br)C=C2)C=C1)=O

Molecular Formula

C17H18BrNO4S

Molecular Weight

412.30

References & Citations

[1]O'Brien PM, et, al. Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors. J Med Chem. 2000 Jan 27;43 (2) :156-66.|[2]Kaludercic N, et, al. Inhibiting metalloproteases with PD 166793 in heart failure: impact on cardiac remodeling and beyond. Cardiovasc Ther. Spring 2008;26 (1) :24-37.|[3]Chancey AL, et, al. Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation. 2002 Apr 23;105 (16) :1983-8.